Suliqua

RSS

insulin glargine / lixisenatide

Authorised
This medicine is authorised for use in the European Union.

Overview

Suliqua is a medicine that is used together with metformin (another diabetes medicine), with or without SGLT-2 inhibitors (other diabetes medicines), for the treatment of adults with type 2 diabetes. It is used with appropriate diet and exercise to improve control of blood glucose (sugar) when the diabetes is not satisfactorily controlled.

The active substances in Suliqua are insulin glargine and lixisenatide.

This EPAR was last updated on 10/09/2020

Authorisation details

Product details
Name
Suliqua
Agency product number
EMEA/H/C/004243
Active substance
  • insulin glargine
  • lixisenatide
International non-proprietary name (INN) or common name
insulin glargine / lixisenatide
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
A10AE
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
sanofi-aventis groupe
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
11/01/2017
Contact address

54 rue La Boetie
75008 Paris
France

Product information

10/08/2020 Suliqua - EMEA/H/C/004243 - IAIN/0015

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Suliqua is indicated in combination with metformin for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose lowering medicinal product or with basal insulin.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating